• Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
  • SKYX Provides Corporate Update
  • Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to  Atezolizumab in Phase 2 Clinical Trial
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
SKYX Provides Corporate Update
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to  Atezolizumab in Phase 2 Clinical Trial
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

PITTSBURGH, Oct. 09, 2024 - PRISM MediaWire - Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman,...
SKYX Provides Corporate Update

MIAMI, Oct. 09, 2024 - PRISM MediaWire - SKYX (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive smart platform technology company with over 97 issued and pending patents in the U.S. and globally, and which owns over 60 lighting and home décor websites with ...
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to  Atezolizumab in Phase 2 Clinical Trial

· Results published in peer-reviewed journal, Clinical Cancer Research
Sono-Tek Announces Fiscal Second Quarter and First Half 2025 Earnings Conference Call

Conference Call on Tuesday, October 15, 2024 at 10:00 am ET
SKYX Secures $11 Million Strategic Investment at $2.00 Per Share, Preferred Stock Convertible, Led by Global Marriott Hotel-Chain Developer, Lance Shaner, Owner of over 60 Hotels, Primarily Marriotts

SKYX Secures $11 Million Strategic Investment at $2.00 Per Share, Preferred Stock Convertible, Led by Global Marriott Hotel-Chain Developer, Lance Shaner, Owner of over 60 Hotels, Primarily Marriotts
AmpliTech Group Announces Receipt of Notice of Allowance for Patents in 5G and Cryogenic Technology For Quantum Computing Applications

Hauppauge, NY, October 7, 2024 - PRISM MediaWire - AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the...
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories
Oncocyte Signs Leading Transplant Centers in US and Germany

· GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volume
Neon Bloom To Partner With Elevated International For 3rd Party Business Development

NEWPORT BEACH, CA, October 2, 2024 - PRISM MediaWire - Neon Bloom, Inc. (OTC PINK: NBCO) announced today that it has finalized a business relationship with Elevated International, a US entity specializing in 3rd party business development.
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth
Social Media

PRISM MediaWire

PRISM MediaWire strives to provide the very best press release, digital media and financial disclosure solutions at highly competitive rates. We earn our clients for the long-term through exemplary service and quality of work. Our press releases include unlimited words, logo, hyperlinks, social media, industry trade circuits and more through the most impactful websites, news agencies, brokerage firms, trading platforms and more. Our services give your company exposure to an audience of millions, including journalists, investors, day-traders, fund managers and social media/messaging platforms. Now your press releases, earnings statements, branded articles, shareholder updates, corporate achievements can reach a vast and diverse audience around the world your Company and shareholders deserve!
            
            

We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
Cookie settings
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
Preferences
Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
Marketing cookies
Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.